Sort publications on year
-
Pharmaco-Economics
Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications
FAGNANI F, LAFUMA A, PECHEVIS M, RIGAUD AS, TRAYKOV L, SEUX ML, FORETTE F
Dement Geriatr Cogn Disord ; 17(1-2):5-13
-
Pharmaco-Economics
Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease
RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FORETTE F
J Geriatr Psychiatry Neurol ; 16(3):140-145
-
Pharmaco-Economics
Patients with Alzheimer’s disease living at home in France : costs and consequences of the disease
RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FLORETTE F
J Geriatr Psychiatry Neurol ; 16(3):140-145
-
Pharmaco-Economics
The Value of Economic Modeling Studies in the Evaluation of Treatment Strategies for Multiple Sclerosis
DETOURNAY B
Value Health ; 5(1):1-2
-
Pharmaco - Epidemiology
Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study
JALLON P, LOISEAU P, LOISEAU J, CAROLE, on behalf of Groupe
Epilepsia ; 2001;42 (4): 464-475
-
Pharmaco - Epidemiology
L’observatoire du traitement mĂ©dical de la maladie d’Alzheimer en neurologie libĂ©rale et les contrĂŽles de qualitĂ© dans les Ă©tudes pharmaco-Ă©pidĂ©miologiques
SIMON T, HINAULT P, GONI S, HOTTON JM, PAUL-DAUPHIN A, GUARD O, DARAN H, JAILLON P
La Lettre du Pharmacologue ; 15(4):74-78
-
Pharmaco-Economics
Les patients atteints d’Alzheimer Ă domicile : coĂ»t et retentissement de la maladie
RIGAUD AS, BAYLE C, FORETTE F, BUTEAU L, FAGNANI F
Gérontologie ; 2001(115): 17-23
-
Pharmaco - Epidemiology
Direct and indirect costs of Parkinson’s Disease (PD) and L-Dopa-Induced Dyskinesia: a Prospective European Study (Abstract)
PECHEVIS M, CLARKE CE, VIEREGGE P, ZIEGLER M, BERDEAUX G, BARLAND JC, J, GARDNER
Parkinsonian & Related Disorders ; 7(P-WE-383):S106
-
Pharmaco-Economics
The contributing factors to medical cost of epilepsy: an estimation based on a French Prospective Cohort study of patients with newly diagnosed epileptic Seizures (The CAROLE study).
DE ZELICOURT M, BUTEAU L, FAGNANI F, JALLON P.
Seizure ; 2000;9(2):88-95
-
Pharmaco-Economics
Evaluation économique du dispositif transdermique de Fentanyl dans la prise en charge de la douleur cancéreuse
PECHEVIS M, EMERY C, FAGNANI F
La Lettre du Pharmacologue ; 14 (1) ; 10-14
-
Pharmaco - Epidemiology
DĂ©lais Ă©volutifs des syndromes Ă©pileptiques avant leur diagnostic : rĂ©sultats descriptifs de l’enquĂȘte CAROLE
Groupe CAROLE
Revue de Neurologie ; 2000;156; (5) : 481-490
-
Pharmaco - Epidemiology
ESPERA study : Applicability of the new ILAE criteria for antiepileptic drug resistance of focal epilepsies in current clinical practice
DE TOFFOL B, DE ZELICOURT M, VESPIGNANI H, FAGNANI F, LAURENDEAU C, LEVY-BACHELOT L, MURAT C, GASALLA T, ARZIMANOGLOU A, VILLANUEVA V
Epilepsy Behav ; 2012;25(2):166-169
-
Pharmaco-Economics
Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study
VILLANUEVA V, GIRĂN JM, MARTĂN J, HERNĂNDEZ-PASTOR LJ, LAHUERTA J, DOZ M, CUESTA M, LĂVY-BACHELOT L; INVESTIGADORES DEL ESTUDIO ESPERA
Neurologia ; 2013;28(4):195-204
-
Pharmaco-Economics
IntĂ©rĂȘt des bases de remboursement de lâAssurance maladie pour lâanalyse de la prise en charge des maladies chroniques : le cas de lâĂ©pilepsie
FAGNANI F, VESPIGNANI H, KUSNIK-JOINVILLE O, BERTRAND M, MURAT C, LEVY-BACHELOT L, KAHANE P
Presse Med ; 2013;42:285-292
-
Pharmaco - Epidemiology
Management of focal epilepsy in adults treated with polytherapy in France : The direct cost of drug resistance (ESPERA study)
DE ZĂLICOURT M, DE TOFFOL B, VESPIGNANI H, LAURENDEAU C, LĂVY-BACHELOT L, MURAT C, FAGNANI F
Seizure ; 2014;23(5):349-356